Literature DB >> 8318816

Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells.

A A Maghazachi1, A al-Aoukaty.   

Abstract

We examined the effect of transforming growth factor-beta 1 (TGF-beta 1) on the in vitro motility of interleukin-2-activated natural killer (IANK) cells. Low doses of TGF-beta 1 (0.01 or 0.1 ng/ml) are chemotactic for these cells as determined by modified Boyden chamber assay. IANK cells bind biotinylated TGF-beta suggesting that they express receptors for this cytokine. TGF-beta 1-induced IANK cell chemotaxis was inhibited by protein kinase C inhibitors, such as staurosporine and H7. The role of calcium mobilization in TGF-beta 1 activity was also examined; the inhibitor of intracellular Ca2+, TMB-8, inhibited TGF-beta 1-induced IANK cell chemotaxis. Supporting the role for Ca2+ mobilization is the ability of low doses of TGF-beta 1 to induce the recruitment of intracellular Ca2+ as determined by a fura-2-AM-loaded-cell assay.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318816

Source DB:  PubMed          Journal:  Nat Immun        ISSN: 1018-8916


  3 in total

Review 1.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

2.  Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

Authors:  M J Maeurer; D M Martin; C Castelli; E Elder; G Leder; W J Storkus; M T Lotze
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

3.  Transforming growth factor beta 1 is an inducer of erythroid differentiation.

Authors:  G Krystal; V Lam; W Dragowska; C Takahashi; J Appel; A Gontier; A Jenkins; H Lam; L Quon; P Lansdorp
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.